← All trials
NCT06345365
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jan 18, 2024
- Primary completion
- Dec 31, 2026
- Completion date
- Dec 31, 2028
- First posted
- Apr 3, 2024
- Last posted
- Apr 10, 2024
- Enrollment
- 154
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Xiamen UniversityLead sponsor
- Xianning Central HospitalCollaborator
- Jingzhou Central HospitalCollaborator
- Wuhan UniversityOfficial
- Shanxi Medical UniversityCollaborator
- Shiyan Taihe HospitalCollaborator
- The First People's Hospital of JingzhouCollaborator
- Jiao Tong UniversityCollaborator
- People's Hospital Of YichangCollaborator
- Zhengzhou UniversityCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.